JP6820743B2 - 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ） - Google Patents

炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ） Download PDF

Info

Publication number
JP6820743B2
JP6820743B2 JP2016539564A JP2016539564A JP6820743B2 JP 6820743 B2 JP6820743 B2 JP 6820743B2 JP 2016539564 A JP2016539564 A JP 2016539564A JP 2016539564 A JP2016539564 A JP 2016539564A JP 6820743 B2 JP6820743 B2 JP 6820743B2
Authority
JP
Japan
Prior art keywords
free
disease
antibody
binding
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016539564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536332A (ja
JP2016536332A5 (https=
Inventor
アンドレア ファイファー
アンドレア ファイファー
バル グレッグ デル
バル グレッグ デル
Original Assignee
エイビー２ バイオ ソシエテアノニム
エイビー２ バイオ ソシエテアノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイビー２ バイオ ソシエテアノニム, エイビー２ バイオ ソシエテアノニム filed Critical エイビー２ バイオ ソシエテアノニム
Publication of JP2016536332A publication Critical patent/JP2016536332A/ja
Publication of JP2016536332A5 publication Critical patent/JP2016536332A5/ja
Application granted granted Critical
Publication of JP6820743B2 publication Critical patent/JP6820743B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
JP2016539564A 2013-09-05 2014-09-05 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ） Active JP6820743B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13183193.5 2013-09-05
EP13183193 2013-09-05
PCT/EP2014/069013 WO2015032932A1 (en) 2013-09-05 2014-09-05 Il-18 binding protein (il-18bp) in inflammatory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019210436A Division JP2020055821A (ja) 2013-09-05 2019-11-21 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）

Publications (3)

Publication Number Publication Date
JP2016536332A JP2016536332A (ja) 2016-11-24
JP2016536332A5 JP2016536332A5 (https=) 2017-08-10
JP6820743B2 true JP6820743B2 (ja) 2021-01-27

Family

ID=49111035

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016539564A Active JP6820743B2 (ja) 2013-09-05 2014-09-05 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）
JP2019210436A Pending JP2020055821A (ja) 2013-09-05 2019-11-21 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019210436A Pending JP2020055821A (ja) 2013-09-05 2019-11-21 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）

Country Status (23)

Country Link
US (3) US10858426B2 (https=)
EP (2) EP3978526A1 (https=)
JP (2) JP6820743B2 (https=)
KR (2) KR102512797B1 (https=)
CN (2) CN115925928A (https=)
AU (1) AU2014317035B2 (https=)
CL (1) CL2016000506A1 (https=)
CY (1) CY1124698T1 (https=)
DK (1) DK3041864T3 (https=)
ES (1) ES2892923T3 (https=)
HU (1) HUE055608T2 (https=)
IL (1) IL244169B (https=)
LT (1) LT3041864T (https=)
MX (1) MX385868B (https=)
NZ (1) NZ717671A (https=)
PH (1) PH12016500425B1 (https=)
PL (1) PL3041864T3 (https=)
PT (1) PT3041864T (https=)
RU (1) RU2731713C2 (https=)
SG (1) SG11201601717VA (https=)
SI (1) SI3041864T1 (https=)
UA (1) UA125204C2 (https=)
WO (1) WO2015032932A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925928A (zh) 2013-09-05 2023-04-07 Ab2生物股份有限公司 炎性疾病中的il-18结合蛋白(il-18bp)
US10882905B2 (en) * 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
DE102016219607B4 (de) * 2016-10-10 2025-04-30 Siemens Healthineers Ag Erzeugung einer mit anatomischen Bilddaten korrelierten Ergebniskarte
WO2019133799A1 (en) * 2017-12-29 2019-07-04 University Of Florida Research Foundation Monoclonal antibodies targeting microtubule-binding domain of tau protein
TWI679279B (zh) * 2018-05-09 2019-12-11 臺中榮民總醫院 檢測成人發作型史笛兒氏症之罹病風險及預後之方法
CA3104362A1 (en) 2018-06-19 2019-12-26 Shanghaitech University Human antibodies to human interleukin 18 receptor alpha and beta
US12269874B2 (en) 2018-12-03 2025-04-08 mAbProtein Co., Ltd. Antibody that recognizes neoepitope of activated interleukin-18 proteins and application thereof
CN110433289B (zh) * 2019-09-10 2024-12-17 中山大学附属口腔医院 用于治疗牙周致病菌感染引起的牙周膜细胞功能紊乱与牙槽骨丧失的药物
IL292443A (en) * 2019-11-04 2022-06-01 Medimmune Ltd Methods for using IL-33 antagonists
US20230173021A1 (en) * 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases
GB202007404D0 (en) * 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
EP4178614A4 (en) * 2020-07-08 2024-10-30 Georgia Tech Research Corporation COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF SARS-COV-2 VIRUS INFECTIONS
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
KR20220044057A (ko) * 2020-09-29 2022-04-06 주식회사 에이프릴바이오 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
JP2023549257A (ja) 2020-11-18 2023-11-22 ノバルティス アーゲー Ｎｌｒｃ４－ｇｏｆインフラマソーム病の処置における使用のための二特異性抗体
WO2022109340A1 (en) * 2020-11-20 2022-05-27 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Immunomodulatory clinical biomarker profiles and uses thereof
EP4371573A4 (en) 2021-07-13 2025-08-20 National Univ Corporation Tokai National Higher Education And Research System MEDICINAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
WO2023067348A1 (en) * 2021-10-21 2023-04-27 Biosirius Ltd Treatment for virally-induced pneumonia
CN114236139A (zh) * 2021-12-30 2022-03-25 苏州和锐生物科技有限公司 一种TNF-α生物制剂的抗体检测试剂盒、制备方法
CA3244428A1 (en) 2022-03-04 2023-09-07 Ab2 Bio Sa IL-18 BINDING PROTEIN (IL-18BP) IN THE TREATMENT OF VEXAS SYNDROME
IL321948A (en) 2023-01-06 2025-09-01 Lassen Therapeutics Inc Anti-IL-18 BP antibodies
EP4646270A2 (en) 2023-01-06 2025-11-12 Alector LLC Anti-il18 binding protein antibodies and methods of use thereof
TW202434634A (zh) * 2023-02-20 2024-09-01 大陸商瑞石生物醫藥有限公司 抗IL-18Rβ抗體、其抗原結合片段及其醫藥應用
AU2024238511A1 (en) * 2023-03-21 2025-10-02 Coya Therapeutics, Inc. Biomarkers of amyotrophic lateral sclerosis and uses thereof
WO2025253161A1 (en) * 2024-06-05 2025-12-11 Aprilbio Co., Ltd. Methods for treating liver diseases using recombinant fusion proteins comprising interleukin-18-binding protein and antigen binding fragment to serum albumin
WO2026038145A1 (en) 2024-08-13 2026-02-19 Ab2 Bio Sa Il-18 binding protein (il-18bp) and methods of using same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
ATE190629T1 (de) 1991-01-18 2000-04-15 Amgen Inc Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
WO1996013590A2 (en) 1994-10-21 1996-05-09 Innogenetics N.V. New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
TWI335336B (https=) 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
NZ520122A (en) * 2000-02-21 2005-04-29 Applied Research Systems Use of IL-18 inhibitors
EE05056B1 (et) 2000-05-05 2008-08-15 Applied Research Systems Ars Holding N.V. IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette n„htud ateroskleroosi ravimiseks ja/v?i ennetamiseks
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
AU2002224417A1 (en) 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
HU229164B1 (en) * 2001-01-29 2013-09-30 Serono Sa Coinsins Lab Use of il-18 inhibitors for the treatment and/or prevention of heart disease
ES2334773T3 (es) * 2001-05-16 2010-03-16 Yeda Research And Development Co. Ltd. Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis.
PL216228B1 (pl) 2001-05-25 2014-03-31 Ares Trading Sa Zastosowanie białka wiążącego IL-18
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20080076708A1 (en) * 2003-05-13 2008-03-27 Valter Altarocca Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
AU2011224023C1 (en) 2003-11-12 2013-08-29 Abbvie Inc. IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
WO2005087249A1 (ja) 2004-03-11 2005-09-22 Kurume University プロテアーゼ阻害剤及び疾患の予防又は治療剤
CA2572921C (en) 2004-07-09 2017-01-03 The University Of North Carolina At Chapel Hill Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants
EP1793859B1 (en) 2004-08-20 2009-03-25 Smithkline Beecham Corporation Treatment of oral and intestinal mucositis by administering human il-18
EP2267024B1 (en) 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DE602006021038D1 (de) 2005-09-15 2011-05-12 Univ Mcgill Verfahren zur diagnose eines ovarialkarzinoms
WO2008091592A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
CA2691039A1 (en) 2007-05-29 2008-12-11 Yale University Il-18 and protein kinase r inhibition for the treatment of copd
KR20140003467A (ko) * 2010-12-20 2014-01-09 메디뮨 리미티드 항il-18 항체 및 그의 용도
US9376489B2 (en) * 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
CN115925928A (zh) 2013-09-05 2023-04-07 Ab2生物股份有限公司 炎性疾病中的il-18结合蛋白(il-18bp)
US10882905B2 (en) * 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases

Also Published As

Publication number Publication date
MX385868B (es) 2025-03-18
KR20160044045A (ko) 2016-04-22
ES2892923T3 (es) 2022-02-07
US20160215048A1 (en) 2016-07-28
US11530263B2 (en) 2022-12-20
SI3041864T1 (sl) 2021-11-30
RU2731713C2 (ru) 2020-09-08
PT3041864T (pt) 2021-10-26
AU2014317035A2 (en) 2016-04-21
US20230250164A1 (en) 2023-08-10
CN105722858A (zh) 2016-06-29
JP2016536332A (ja) 2016-11-24
LT3041864T (lt) 2021-10-11
NZ717671A (en) 2022-07-01
HUE055608T2 (hu) 2021-12-28
US20200392222A1 (en) 2020-12-17
EP3041864B1 (en) 2021-07-21
SG11201601717VA (en) 2016-04-28
DK3041864T3 (da) 2021-09-27
JP2020055821A (ja) 2020-04-09
AU2014317035A1 (en) 2016-03-10
US10858426B2 (en) 2020-12-08
PL3041864T3 (pl) 2021-12-20
PH12016500425A1 (en) 2016-05-23
PH12016500425B1 (en) 2022-07-29
KR102321172B1 (ko) 2021-11-05
KR102512797B1 (ko) 2023-03-22
CA2922498A1 (en) 2015-03-12
CY1124698T1 (el) 2022-07-22
EP3041864A1 (en) 2016-07-13
KR20210132749A (ko) 2021-11-04
CL2016000506A1 (es) 2016-09-23
RU2016112596A (ru) 2017-10-09
EP3978526A1 (en) 2022-04-06
CN115925928A (zh) 2023-04-07
UA125204C2 (uk) 2022-02-02
AU2014317035B2 (en) 2020-02-27
IL244169A0 (en) 2016-04-21
HK1221726A1 (zh) 2017-06-09
IL244169B (en) 2019-12-31
MX2016002719A (es) 2016-09-06
WO2015032932A1 (en) 2015-03-12
BR112016004772A2 (https=) 2017-09-05
RU2016112596A3 (https=) 2018-07-18

Similar Documents

Publication Publication Date Title
JP6820743B2 (ja) 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）
US11820817B2 (en) IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
JP2018509153A (ja) Ｔｓｌｐ結合タンパク質
JP2020000236A (ja) ヒトペリオスチンを検出する新規アッセイ
CA2922498C (en) Il-18 binding protein (il-18bp) in inflammatory diseases
HK1221726B (en) Il-18 binding protein (il-18bp) in inflammatory diseases
BR112016004772B1 (pt) Método para determinação da quantidade de il-18 livre em uma amostra ou in situ, uso de um inibidor de il-18, e, kit de diagnóstico para detectar il-18 livre
RU2810206C1 (ru) Il-18-связывающий белок (il-18bp) и антитела при воспалительных заболеваниях
JP2025507007A (ja) Ｖｅｘａｓの治療におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）
BR112017017076B1 (pt) Uso de il-18bp

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191121

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20191121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191122

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191223

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20191225

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200214

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200219

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200902

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201012

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20201125

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20201224

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20201224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210105

R150 Certificate of patent or registration of utility model

Ref document number: 6820743

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250